Secondary analysis of DEPROMP: in 230 biopsy-naïve men having systematic, MRI- and PSMA PET/CT-targeted biopsy, 94.8% had no post-biopsy symptoms and AEs were mostly low-grade. At 6 months 29.5% reported worse quality of life, linked to cancer diagnosis (OR 12.94), not AEs.
Secondary analysisn = 230
Schmidt et al. Safety and patient-reported outcomes of multimodal PSMA PET/MRI-guided prostate biopsy: results from the prospective multicenter DEPROMP trial